ICH E6(R3) Annex 2: Good Clinical Practice for Decentralised, Pragmatic and Real-World Data Trials

ICH finalised Annex 2 to the E6(R3) Good Clinical Practice guideline on 3 June 2026. Where the core E6(R3) principles and Annex 1 describe GCP for conventional interventional trials, Annex 2 addresses how those principles apply when trials use decentralised elements, pragmatic design features or real-world data. For sponsors running trials in Greece and across the EU, it sets the reference point for designs that inspectors and ethics committees are increasingly seeing.

What Annex 2 covers

Annex 2 supplements, rather than replaces, the E6(R3) principles and Annex 1. It covers three areas:

  • Decentralised elements: trial activities carried out away from the investigator site, such as remote visits, home nursing, direct-to-patient supply of investigational product and digital data collection tools.
  • Pragmatic elements: design features that bring a trial closer to routine care, such as broader eligibility, streamlined data collection and delivery within normal healthcare settings.
  • Real-world data: the use of data from sources such as electronic health records, registries and claims databases within an interventional trial.

Key expectations

  • Risk-proportionate oversight. Oversight should be scaled to the risk each activity poses to participants and to the reliability of results, consistent with the quality-by-design approach of E6(R3).
  • Fitness for purpose of real-world data. Each data source should be assessed for relevance and reliability, and sponsors need appropriate, documented access to the data and its provenance, including where third parties hold it.
  • Remote consent with safeguards. Remote informed consent is acceptable where identity verification is planned in advance, and participants should have an alternative route.
  • Safety information that reaches investigators. When data flow from several sources, the sponsor must ensure that relevant safety information reaches investigators in a timely and usable way.
  • Clear roles. Home-care providers, technology vendors and data holders need defined responsibilities, contracts and oversight.

Implementation in the EU and US

ICH guidelines take effect once each regulator implements them. EMA will publish its own effective date for Annex 2, and FDA has not yet issued Annex 2 as final guidance. Sponsors should track both, and remember that in the EU, national requirements under the Clinical Trials Regulation, for example on home administration and direct-to-patient shipment, continue to apply alongside GCP.

Practical steps for sponsors

  • Map which decentralised or real-world data elements your protocols already use
  • Update risk assessments and monitoring plans to cover off-site activities and data flows
  • Review vendor contracts for data access, audit rights and safety reporting
  • Check national requirements in each member state concerned before building a decentralised design

How PQRA helps

PQRA supports sponsors with clinical trial applications in Greece and the EU, GCP gap assessments against E6(R3), vendor oversight and safety reporting processes for trials that combine site-based, remote and real-world data elements.

Contact PQRA about E6(R3) readiness

CATEGORIES:

Uncategorized

Tags:

No responses yet

Leave a Reply

Your email address will not be published. Required fields are marked *